Compare IPCA Labs with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STRIDES PHARMA SCIENCE - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STRIDES PHARMA SCIENCE IPCA LABS/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 24.2 47.9 50.5% View Chart
P/BV x 8.7 2.2 387.0% View Chart
Dividend Yield % 0.1 0.2 64.5%  

Financials

 IPCA LABS   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    IPCA LABS
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
IPCA LABS/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,0421,147 90.8%   
Low Rs590642 91.9%   
Sales per share (Unadj.) Rs298.6317.2 94.1%  
Earnings per share (Unadj.) Rs35.07.8 446.2%  
Cash flow per share (Unadj.) Rs49.425.1 197.3%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %0.40.2 164.4%  
Book value per share (Unadj.) Rs247.1274.3 90.1%  
Shares outstanding (eoy) m126.3589.50 141.2%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.72.8 96.9%   
Avg P/E ratio x23.3114.0 20.4%  
P/CF ratio (eoy) x16.535.7 46.2%  
Price / Book Value ratio x3.33.3 101.2%  
Dividend payout %8.625.5 33.6%   
Avg Mkt Cap Rs m103,10880,058 128.8%   
No. of employees `00013.42.5 536.2%   
Total wages/salary Rs m7,8744,341 181.4%   
Avg. sales/employee Rs Th2,807.011,325.8 24.8%   
Avg. wages/employee Rs Th585.81,731.4 33.8%   
Avg. net profit/employee Rs Th329.0280.1 117.5%   
INCOME DATA
Net Sales Rs m37,73228,394 132.9%  
Other income Rs m577941 61.3%   
Total revenues Rs m38,30929,334 130.6%   
Gross profit Rs m6,9013,965 174.0%  
Depreciation Rs m1,8241,540 118.4%   
Interest Rs m1891,962 9.6%   
Profit before tax Rs m5,4651,403 389.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,04297 1,071.3%   
Profit after tax Rs m4,422702 629.9%  
Gross profit margin %18.314.0 131.0%  
Effective tax rate %19.16.9 275.1%   
Net profit margin %11.72.5 474.0%  
BALANCE SHEET DATA
Current assets Rs m23,77824,836 95.7%   
Current liabilities Rs m10,97518,993 57.8%   
Net working cap to sales %33.920.6 164.9%  
Current ratio x2.21.3 165.7%  
Inventory Days Days10471 146.2%  
Debtors Days Days66113 58.1%  
Net fixed assets Rs m20,36834,289 59.4%   
Share capital Rs m253895 28.2%   
"Free" reserves Rs m30,97123,651 131.0%   
Net worth Rs m31,22424,546 127.2%   
Long term debt Rs m1,40915,513 9.1%   
Total assets Rs m45,50765,437 69.5%  
Interest coverage x30.01.7 1,746.8%   
Debt to equity ratio x00.6 7.1%  
Sales to assets ratio x0.80.4 191.1%   
Return on assets %10.14.1 248.8%  
Return on equity %14.22.9 495.1%  
Return on capital %17.36.9 251.3%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30815,697 110.3%   
Fx outflow Rs m6,266735 852.1%   
Net fx Rs m11,04214,962 73.8%   
CASH FLOW
From Operations Rs m4,9231,871 263.2%  
From Investments Rs m-1,5635,826 -26.8%  
From Financial Activity Rs m-1,832-10,157 18.0%  
Net Cashflow Rs m1,528-2,615 -58.4%  

Share Holding

Indian Promoters % 45.9 27.7 165.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 37.8 30.2%  
FIIs % 25.3 8.6 294.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 25.9 67.2%  
Shareholders   36,892 56,241 65.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  GSK PHARMA  UNICHEM LAB  ORCHID PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 16, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - ORCHID PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS